



**Date: March 11, 2024**

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Script Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject:** Press Release

---

We are pleased to inform that Mankind Pharma Limited & AstraZeneca Pharma India Limited have signed today Distribution and Promotion agreement for the distribution of budesonide and formoterol fumarate dihydrate (brand name Symbicort).

Please find enclosed herewith Press Release titled “AstraZeneca Pharma India Ltd and Mankind Pharma partner to accelerate access to asthma medicine for patients in India”, which we shall be releasing after sending this letter to you.

Request you to kindly take the above on record.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Pradeep Chugh**  
**Company Secretary and Compliance Officer**

## AstraZeneca Pharma India Ltd and Mankind Pharma partner to accelerate access to asthma medicine for patients in India

**Bangalore, India: March 11 2024** - AstraZeneca Pharma India Limited (AstraZeneca India) (BSE : 506820, NSE : ASTRAZEN) and Mankind Pharma Limited (BSE: 543904 | NSE: MANKIND) entered into an agreement for exclusive distribution of AstraZeneca's budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license.

India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths. It highlights a clear scope of improving the way asthma is managed in the country<sup>1</sup>. " Our aspiration is to be pioneers in science and lead in specialist disease areas. We are focused on transforming outcomes for patients and contributing sustainably to people, society and the planet. The partnership with Mankind Pharma presents an opportunity to accelerate access and maximize the potential of our asthma drug as well as the turbuhaler which is a simple device<sup>2</sup>, efficient in consistently delivering a higher proportion of respirable particles than the other devices. As much as we are excited to bring innovative medicine to India fast, we are equally invested on improving access strategically in the country" said **Dr. Sanjeev Panchal, Managing Director and Country President of AstraZeneca India.**

With an expansive distribution network including close to 16,000 field force and more than 13,000 stockists across India, Mankind Pharma has positioned itself as a leader in ensuring availability and access to quality pharmaceuticals across the country, including small towns and rural areas. **Commenting on the agreement with AstraZeneca India, Mr Atish Majumdar, Sr. President – Sales & Marketing, Mankind Pharma Limited said** "Mankind has always been steadfast in providing access to quality treatments to the deserving patients across the nation. In this regard, we are excited to partner with AstraZeneca to make their innovative therapy flagship brand Symbicort, a global standard in treating Asthma. Symbicort's dual mechanism of action and ease of use in a single inhaler can greatly help patients manage these conditions and improve their quality of life. Through our field forces' extensive outreach, we hope to strengthen access across urban and rural markets. With our shared goal to enable better patient outcomes, I see this collaboration as strategic in more ways than one. We believe such credible partnerships that widen availability of globally established medicines in India exemplify our ethos of putting patients first while ensuring value."

Globally AstraZeneca is an established leader in respiratory care, a disruptor in immunology and will continue to transform care for some of the most debilitating and chronic respiratory and immune-mediated diseases. With an ambition to transform Respiratory & Immunology care for patients in India, moving beyond symptom control to disease modification, remission and, one day, cure, AstraZeneca India is focused to be number 1 in respiratory Biologics.

AstraZeneca is present in therapy areas including Oncology; BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology); and Rare Disease in India and is focused on transforming the future of healthcare by unlocking the power of what science can do for people, society and planet.

1. Lung India 2022;39:331-6
2. Lars Thorssona et.al, Respiratory Medicine (2005) 99, 836–849;
3. Lars Thorssona et.al, Respiratory Medicine (2005) 99, 836–849;

### **About AstraZeneca Pharma India Ltd**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Biopharmaceuticals and Rare Diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Established in 1979, it is headquartered at Bengaluru, Karnataka and has a workforce of over 900 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: [www.astrazeneca.in](http://www.astrazeneca.in)

### **About Mankind Pharma**

Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. The company has 28 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 600 scientists. For more information, visit [www.mankindpharma.com](http://www.mankindpharma.com)

### **For media queries please contact:**

#### **AstraZeneca Pharma India Ltd**

**Sindhu Manivannan-9873712924-[sindhu.manivannan@astrazeneca.com](mailto:sindhu.manivannan@astrazeneca.com)**

#### **Mankind Pharma**

**Natasha Raj- 9205057627- [natasha.raj@mankindpharma.com](mailto:natasha.raj@mankindpharma.com)**

**Apoorva Sharma- 9999739452- [apoorva.sharma@adfactorspr.com](mailto:apoorva.sharma@adfactorspr.com)**

1. Lung India 2022;39:331-6
2. Lars Thorssona et.al, Respiratory Medicine (2005) 99, 836–849;
3. Lars Thorssona et.al, Respiratory Medicine (2005) 99, 836–849;